Monlunca (Lutetium (177lu) Chloride)

Lutetium-177 chloride, the active ingredient in Monlunca, is a radiopharmaceutical presented as a sterile solution for intravenous use. It delivers targeted radiation to malignant cells in patients with specific oncologic conditions. GNH USA supplies Monlunca as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Monlunca is employed in radionuclide therapy for tumors that express specific molecular targets. - Gastroenteropancreatic neuroendocrine tumors: provides localized radiation to reduce tumor burden and control disease progression. - Metastatic neuroendocrine tumors: delivers beta‑particle emission to shrink metastatic lesions and alleviate symptoms. - PSMA‑positive metastatic prostate cancer: targets prostate‑specific membrane antigen to deliver cytotoxic radiation to cancer cells.

Adverse reactions are related to radiation exposure and the carrier molecule used for targeting.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset after administration. - Fatigue: transient tiredness lasting days to weeks. - Transient hematologic changes: temporary reduction in blood cell counts. - Mild renal function changes: slight increase in serum creatinine. - Injection site discomfort: brief pain or irritation at the infusion site.

Serious or Rare Side Effects: - Severe bone marrow suppression: prolonged pancytopenia requiring medical intervention. - Renal toxicity: significant decline in kidney function. - Hepatotoxicity: elevated liver enzymes indicating liver injury. - Allergic reactions: anaphylaxis or severe hypersensitivity to the carrier molecule.

Prior to therapy, patients should be evaluated for organ function and potential contraindications. - Renal assessment: ensure adequate kidney function before dosing. - Hematologic monitoring: baseline blood counts required to detect marrow suppression. - Pregnancy avoidance: women of childbearing potential must use effective contraception. - Radiation safety: follow institutional protocols to protect staff and family members. - Drug interactions: review concurrent therapies that may exacerbate hematologic or renal effects. Store at ambient temperature: keep in original container, protect from light and moisture, and avoid freezing.

Lutetium‑177 chloride may interact with drugs that affect blood cell production or renal clearance.

Major Interactions (Avoid): - Myelosuppressive chemotherapy: concurrent use can cause severe bone marrow failure. - Nephrotoxic agents (e.g., high‑dose cisplatin): may exacerbate renal toxicity.

Moderate Interactions (Monitor Closely): - Anticoagulants: monitor for increased bleeding risk due to thrombocytopenia. - ACE inhibitors or ARBs: watch renal function closely. - Immunosuppressants: assess infection risk as leukopenia may be compounded.